Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GS 9411 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 09 May 2014 New trial record